Get the Stockscreener App
220.08
1.81%
-4.05
After Hours:
220.91
0.83
+0.38%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $220.08, with a volume of 6.54M.
It is down -1.81% in the last 24 hours and down -1.30% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$224.13
Open:
$223.75
24h Volume:
6.54M
Relative Volume:
1.16
Market Cap:
$388.97B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
166.06
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-4.03%
1M Performance:
-1.30%
6M Performance:
+15.45%
1Y Performance:
+23.29%
1-Day Range:
$219.00
$225.12
1-Week Range:
$217.86
$237.04
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.08 | 396.12B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,063.56 | 971.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.39 | 495.71B | 92.15B | 25.12B | 20.46B | 10.36 |
|
MRK
Merck Co Inc
|
110.53 | 275.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.54 | 271.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
J&J Joins Trump Administration’s MFN Pricing Initiative - Citeline News & Insights
Revolution Medicines Soars Amid AbbVie Acquisition Talks - StocksToTrade
What Catalysts Could Shift AbbVie’s Story As Analysts Rework Targets And Drug Expectations - Yahoo Finance
AbbVie Expands Bid to Block Qulipta Copies With Two Patent Suits - Bloomberg Law News
Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks - Stocktwits
AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV - TechStock²
AbbVie Inc. Bets Big on Immunology and Oncology: How Its Drug Portfolio Became the Real Flagship Pro - AD HOC NEWS
Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. - Barron's
Here's What We Expect From AbbVie's Immunology Segment in Q4 - The Globe and Mail
Merck in Talks to Buy Biotech Revolution Medicines, FT Says - Bloomberg.com
Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. - Barron's
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga
Revolution Medicines jumps on report AbbVie nears takeover - MSN
AbbVie Inc.: How a Pharma Powerhouse Is Re?Engineering Its Future Beyond Humira - AD HOC NEWS
AbbVie Sues Over Bids To Market Generic Migraine Drugs - Law360
Merck in Deal Talks With Biotech Revolution Medicines, FT Says - Bloomberg.com
Key facts: AbbVie revises EPS guidance; negotiates $20B acquisition - TradingView — Track All Markets
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders - TechStock²
AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial - Benzinga
AbbVie: The Dividend Does Not Lie (NYSE:ABBV) - Seeking Alpha
AbbVie (ABBV) Warns of Q4 Earnings Impact Due to $1.3B Charge - GuruFocus
AbbVie sees negative Q4 EPS impact from IPR&D expenses - MSN
Merck rises as Wolfe upgrades to Outperform; AbbVie downgraded - Seeking Alpha
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail - Sherwood News
AbbVie Flags $1.3B Charge, Cuts Fourth-Quarter EPS Outlook - Yahoo Finance
AbbVie, Revolution Medicines Stocks Fall After Drugmaker Denies Takeover Report - Barron's
Aug Big Picture: Can AbbVie Inc. stock continue upward trendDividend Hike & Accurate Trade Setup Notifications - ulpravda.ru
Lockheed, Northrop, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked inWolfe - Investing.com India
AbbVie (ABBV) Stock Falls After Company Denies Revolution Medicines Buyout Talks - Blockonomi
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
Northrop, Lockheed, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story? - Yahoo Finance
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down - TechStock²
Revolution Medicines dips after AbbVie denies takeover talks - TradingView — Track All Markets
AbbVie (ABBV) Stock Drops as Company Denies Revolution Medicines Acquisition Reports - CoinCentral
AbbVie Lowers Q4, 2025 Adjusted EPS Guidance - MarketScreener
Why Revolution Medicines Shares Are Sliding After Hours On Wednesday - Benzinga
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
AbbVie (ABBV) Projects Q4 Earnings Impact from $1.3 Billion Char - GuruFocus
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie flags $1.3B IPR&D charge, warns of Q4 earnings pressure (ABBV:NYSE) - Seeking Alpha
Revolution Medicines Stock Pre-Market (-6.0%): AbbVie Denies Acquisition Talks - Trefis
AbbVie Denies Media Reports of Talks to Buy Revolution Medicines - MarketScreener
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
AbbVie denies media reports of talks to buy Revolution Medicines - WTVB
Exclusive | Revolution Medicines Draws Takeover Interest - The Wall Street Journal
Stock Movers: Jeffries, AbbVie, Raytheon - Bloomberg.com
AbbVie2025 adjusted EPS guidance range $9.90$9.94SEC filing - MarketScreener
Revolution Medicines (RVMD) Shares Plunge After AbbVie Denies Acquisition Talks - GuruFocus
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):